SE0201778D0 - Process for the manufacture of quinoline derivatives - Google Patents

Process for the manufacture of quinoline derivatives

Info

Publication number
SE0201778D0
SE0201778D0 SE0201778A SE0201778A SE0201778D0 SE 0201778 D0 SE0201778 D0 SE 0201778D0 SE 0201778 A SE0201778 A SE 0201778A SE 0201778 A SE0201778 A SE 0201778A SE 0201778 D0 SE0201778 D0 SE 0201778D0
Authority
SE
Sweden
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
SE0201778A
Other languages
English (en)
Swedish (sv)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0201778A priority Critical patent/SE0201778D0/xx
Publication of SE0201778D0 publication Critical patent/SE0201778D0/xx
Priority to DE60310554T priority patent/DE60310554T2/de
Priority to MEP-2008-656A priority patent/ME00435B/fr
Priority to YUP-1076/04A priority patent/RS51021B/sr
Priority to CNB038135310A priority patent/CN100418950C/zh
Priority to DK03725956T priority patent/DK1511732T5/da
Priority to UA20041109639A priority patent/UA78310C2/xx
Priority to KR1020047020088A priority patent/KR100979216B1/ko
Priority to MXPA04012276A priority patent/MXPA04012276A/es
Priority to HRP20050028AA priority patent/HRP20050028B1/hr
Priority to NZ536768A priority patent/NZ536768A/en
Priority to EP03725956A priority patent/EP1511732B9/fr
Priority to PT03725956T priority patent/PT1511732E/pt
Priority to AU2003228195A priority patent/AU2003228195B2/en
Priority to PCT/SE2003/000780 priority patent/WO2003106424A1/fr
Priority to PL373817A priority patent/PL210259B1/pl
Priority to SI200330688T priority patent/SI1511732T1/sl
Priority to AT03725956T priority patent/ATE348814T1/de
Priority to ES03725956T priority patent/ES2278160T3/es
Priority to JP2004513257A priority patent/JP4584709B2/ja
Priority to RU2005100054/04A priority patent/RU2291861C2/ru
Priority to CA2487329A priority patent/CA2487329C/fr
Priority to BRPI0311674-3A priority patent/BR0311674A/pt
Priority to IL165155A priority patent/IL165155A/en
Priority to ZA200409430A priority patent/ZA200409430B/xx
Priority to IS7550A priority patent/IS2975B/is
Priority to NO20045703A priority patent/NO329162B1/no
Priority to CY20071100295T priority patent/CY1107555T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0201778A 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives SE0201778D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
BRPI0311674-3A BR0311674A (pt) 2002-06-12 2003-05-14 processo para a preparação de compostos
PT03725956T PT1511732E (pt) 2002-06-12 2003-05-14 Processo para o fabrico de derivados quinolina
PCT/SE2003/000780 WO2003106424A1 (fr) 2002-06-12 2003-05-14 Methode de production de derives de quinoline
YUP-1076/04A RS51021B (sr) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina
CNB038135310A CN100418950C (zh) 2002-06-12 2003-05-14 制备喹啉衍生物的方法
DK03725956T DK1511732T5 (da) 2002-06-12 2003-05-14 Fremgangsmåde til fremstilling af quinolinderivater
UA20041109639A UA78310C2 (en) 2002-06-12 2003-05-14 Method for preparing quinolin derivatives
KR1020047020088A KR100979216B1 (ko) 2002-06-12 2003-05-14 퀴놀린 유도체의 제조 방법
MXPA04012276A MXPA04012276A (es) 2002-06-12 2003-05-14 Proceso para la elaboracion de derivados de quinolina.
HRP20050028AA HRP20050028B1 (hr) 2002-06-12 2003-05-14 Postupak za proizvodnju derivata kinolina
NZ536768A NZ536768A (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline carboxamide derivatives using an alkane or cycloalkane solvent
EP03725956A EP1511732B9 (fr) 2002-06-12 2003-05-14 Methode de production de derives de quinoline
DE60310554T DE60310554T2 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
AU2003228195A AU2003228195B2 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
MEP-2008-656A ME00435B (fr) 2002-06-12 2003-05-14 Methode de production de derives de quinoline
PL373817A PL210259B1 (pl) 2002-06-12 2003-05-14 Sposób wytwarzania pochodnych chinoliny
SI200330688T SI1511732T1 (sl) 2002-06-12 2003-05-14 Postopek za pripravo kinolinskih derivatov
AT03725956T ATE348814T1 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
ES03725956T ES2278160T3 (es) 2002-06-12 2003-05-14 Procedimiento para la fabricacion de derivados de quinolina.
JP2004513257A JP4584709B2 (ja) 2002-06-12 2003-05-14 キノリン誘導体の製造工程
RU2005100054/04A RU2291861C2 (ru) 2002-06-12 2003-05-14 Способ получения производных хинолина
CA2487329A CA2487329C (fr) 2002-06-12 2003-05-14 Methode de production de derives de quinoline
IL165155A IL165155A (en) 2002-06-12 2004-11-11 A process to create a history of quinoline
ZA200409430A ZA200409430B (en) 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives.
IS7550A IS2975B (is) 2002-06-12 2004-11-24 Aðferð til framleiðslu á kvínólín-afleiðum
NO20045703A NO329162B1 (no) 2002-06-12 2004-12-29 Fremgangsmate ved fremstilling av quinolin-derivater
CY20071100295T CY1107555T1 (el) 2002-06-12 2007-03-01 Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
SE0201778D0 true SE0201778D0 (sv) 2002-06-12

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Country Status (28)

Country Link
EP (1) EP1511732B9 (fr)
JP (1) JP4584709B2 (fr)
KR (1) KR100979216B1 (fr)
CN (1) CN100418950C (fr)
AT (1) ATE348814T1 (fr)
AU (1) AU2003228195B2 (fr)
BR (1) BR0311674A (fr)
CA (1) CA2487329C (fr)
CY (1) CY1107555T1 (fr)
DE (1) DE60310554T2 (fr)
DK (1) DK1511732T5 (fr)
ES (1) ES2278160T3 (fr)
HR (1) HRP20050028B1 (fr)
IL (1) IL165155A (fr)
IS (1) IS2975B (fr)
ME (1) ME00435B (fr)
MX (1) MXPA04012276A (fr)
NO (1) NO329162B1 (fr)
NZ (1) NZ536768A (fr)
PL (1) PL210259B1 (fr)
PT (1) PT1511732E (fr)
RS (1) RS51021B (fr)
RU (1) RU2291861C2 (fr)
SE (1) SE0201778D0 (fr)
SI (1) SI1511732T1 (fr)
UA (1) UA78310C2 (fr)
WO (1) WO2003106424A1 (fr)
ZA (1) ZA200409430B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG10201508623RA (en) 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
WO2009082471A1 (fr) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Préparations de laquinimod stables
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
US20120009226A1 (en) * 2008-12-17 2012-01-12 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
ES2564931T3 (es) 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (fr) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Traitement de troubles lies au fndc au moyen de laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
WO2011109526A1 (fr) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Traitement de la néphrite de lupus à l'aide du laquinimod
MX2012010066A (es) 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
EP2590949B1 (fr) * 2010-07-09 2015-11-25 Active Biotech AB Procédé pour la fabrication de quinoléine-3-carboxamides
EA201390074A1 (ru) * 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2537517A1 (fr) * 2011-06-22 2012-12-26 Active Biotech AB 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide enrichie au deuterium
EP2766020A4 (fr) 2011-10-12 2015-04-01 Teva Pharma Traitement de la sclérose en plaques par combinaison de laquinimod et de fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
EP2970129A2 (fr) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Cristaux de sodium de laquinimod et procédé amélioré pour leur fabrication
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
WO2016042112A1 (fr) 2014-09-23 2016-03-24 Active Biotech Ab Quinoléine carboxamides destinées à être utilisées dans le traitement du myélome multiple
ES2663836T3 (es) 2014-11-19 2018-04-17 Active Biotech Ab Carboxamidas de quinolina para su uso en el tratamiento de leucemia
CA3168070A1 (fr) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod ou sel pharmaceutiquement acceptable de celui-ci destine a etre utilise en polytherapie
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
AU2021313388A1 (en) 2020-07-23 2023-01-19 Erasmus University Medical Center Rotterdam (Erasmus Mc) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
PL4277628T3 (pl) 2021-01-18 2026-02-09 Active Biotech Ab Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego
JP2024520307A (ja) 2021-05-25 2024-05-24 アクティブ バイオテック エイビー 複数のタスキニモド粒子およびその使用
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
HRP20050028A2 (en) 2006-02-28
BR0311674A (pt) 2008-01-08
ME00435B (fr) 2011-10-10
IL165155A (en) 2009-11-18
AU2003228195B2 (en) 2009-05-28
KR100979216B1 (ko) 2010-08-31
RU2291861C2 (ru) 2007-01-20
ZA200409430B (en) 2006-02-22
ES2278160T3 (es) 2007-08-01
RS51021B (sr) 2010-10-31
NZ536768A (en) 2006-10-27
EP1511732A1 (fr) 2005-03-09
AU2003228195A1 (en) 2003-12-31
PL373817A1 (en) 2005-09-19
WO2003106424A1 (fr) 2003-12-24
EP1511732B9 (fr) 2008-11-12
DE60310554T2 (de) 2007-11-29
PT1511732E (pt) 2007-03-30
CA2487329C (fr) 2010-11-16
HRP20050028B1 (hr) 2013-07-31
KR20050016537A (ko) 2005-02-21
MXPA04012276A (es) 2005-04-08
CN100418950C (zh) 2008-09-17
SI1511732T1 (sl) 2007-06-30
NO20045703L (no) 2004-12-29
JP4584709B2 (ja) 2010-11-24
RU2005100054A (ru) 2005-07-10
DE60310554D1 (de) 2007-02-01
CN1659146A (zh) 2005-08-24
UA78310C2 (en) 2007-03-15
EP1511732B1 (fr) 2006-12-20
CY1107555T1 (el) 2013-03-13
IS2975B (is) 2017-07-15
NO329162B1 (no) 2010-08-30
IL165155A0 (en) 2005-12-18
DK1511732T5 (da) 2007-10-01
ATE348814T1 (de) 2007-01-15
IS7550A (is) 2004-11-24
RS107604A (sr) 2007-02-05
DK1511732T3 (da) 2007-04-30
CA2487329A1 (fr) 2003-12-24
PL210259B1 (pl) 2011-12-30
JP2005535612A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
DK1511732T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EA200700545A1 (ru) Производные изоксазолина и их применение в качестве гербицидов
DK1613304T3 (da) DPP-IV-inhibitorer
EP1674452A4 (fr) Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
DK1601653T3 (da) Fremgangsmåde til fremstilling af substituerede nikotinsyreestre
NO20054787L (no) Indenderivater som farmasotiske midler
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
MY141020A (en) Novel pparalpha and ppargamma agonists
WO2003024913A1 (fr) Derives d'acides benzoiques substitues possedant une activite d'inhibition de nf-kb
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
PE20010029A1 (es) Androgenos oralmente activos
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
NO20054875L (no) Syntese av 2-klormetyl-6-metylbenzosyreestere
EA200100155A2 (ru) Новые производные 6-амино или 6-гидразиносульфонил-3-хинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции
ES2184633A1 (es) Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
TH72657A (th) สารประกอบ
IS8017A (is) Nítratesterar fenýlamínóþíófenediksýruafleiða